---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-250698"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:10:25.216569+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics sells avasopasem and rucosopasem assets to Biossil Inc.

## Summary
- Sold all dismutase mimetic assets including avasopasem (GC4419) and rucosopasem (GC4711) to Biossil Inc., a Canadian company.
- Transaction closed Oct 15, 2025; Blackstone Agreement assigned to Biossil on Oct 21, 2025.
- Blackstone will look solely to Biossil for all obligations under the Amended Blackstone Agreement; Galera relieved of those liabilities.
- No purchase price or deal financial terms disclosed in the filing.

## SEC filing metadata
- accession: 0001193125-25-250698
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312525250698/0001193125-25-250698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312525250698/d904873d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-250698
- JSON: https://secwatch.observer/filing/0001193125-25-250698.json
- Plain text: https://secwatch.observer/filing/0001193125-25-250698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.